Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands

IndustryPRwire -- Alimera Sciences announces that Alimera Sciences Europe Limited, its Irish subsidiary, has launched ILUVIEN® in the Netherlands. Alimera’s distribution partner Horus Pharma S.A.S. (Horus) has secured pricing and reimbursement and will begin selling ILUVIEN this month in the Netherlands for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU).

Rick Eiswirth, Alimera’s President and Chief Executive Officer Commented “We are continuing to execute our strategy of geographic expansion, making ILUVIEN available for more physicians and patients in new markets, We are excited to work with our partner, Horus Pharma, who has been preparing for this launch of ILUVIEN over the past several months and is applying learnings from their highly successful launch in France.”

ILUVIEN is a sustained release intravitreal implant indicated in several European countries for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).

Maja Lausevic, Chief Operating Officer, Horus Pharma Commented “We anticipate a successful launch in the Netherlands as we expand our collaboration with Alimera Sciences for the marketing and distribution of ILUVIEN in another European territory, Access to ILUVIEN therapy and the benefits of its CONTINUOUS MICRODOSING™ technology is already broadly anticipated by local ophthalmologists. In fact, patients have already been scheduled for injection.”

Prof. Carel B. Hoyng, Radboud University Medical Center, Nijmegen, The Netherlands Commented "As a long-lasting steroid, ILUVIEN will be very useful for patients who suffer from DME and uveitis affecting the posterior segment, Patients have been waiting for a long-lasting treatment and ILUVIEN provides an opportunity to decrease the burden of injections."

Related Posts

Subscribe Our Newsletter